Bictegravir is an integrase strand transfer inhibitor (INSTI) used in combination therapy to treat HIV-1 infection by blocking the viral enzyme integrase, which prevents the virus from inserting its DNA… Read more




![Chemical structure of N-(2,6-Difluorobenzyl)-8-hydroxy-7,9-dioxo-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2FN-26-Difluorobenzyl-8-hydroxy-79-dioxo-2345791313a-octahydro-25-methanopyrido1245pyrazino21-b13oxazepine-10-carboxamide.png&w=3840&q=75)




Bictegravir is an integrase strand transfer inhibitor (INSTI) used in combination therapy to treat HIV-1 infection by blocking the viral enzyme integrase, which prevents the virus from inserting its DNA into the host genome. This category contains essential reference standards for Bictegravir, including its pharmacopeial and non-pharmacopeial impurities, metabolites, diastereomers, and stable isotope-labelled compounds. Pharmaceutical laboratories utilize these high-purity reference materials for critical analytical tasks, including impurity profiling, method validation, and rigorous quality control. Stable isotope-labelled compounds are particularly valuable in mass spectrometry for accurate quantification by compensating for matrix effects. These standards support the characterization of degradation products formed through hydrolysis, oxidation, or photolysis, helping researchers ensure that drug products meet regulatory ICH guidelines for safety and stability throughout the drug development lifecycle.